Lorlatinib is an anaplastic lymphoma kinase (ALK) inhibitor used to treat advanced non-small cell lung cancer (NSCLC) with ALK gene alterations. It works by inhibiting ALK signaling pathways, leading to cancer cell death. This medication is vital for managing specific types of lung cancer. In summary, Lorlatinib is effective in treating advanced NSCLC.
Lorlatinib inhibits ALK tyrosine kinase activity, disrupting downstream signaling pathways essential for cancer cell survival.
No published brands for this salt yet.